PMID- 15246623
OWN - NLM
STAT- MEDLINE
DCOM- 20041018
LR  - 20131121
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 22
IP  - 21-22
DP  - 2004 Jul 29
TI  - Identification of adjuvants that enhance the therapeutic antibody response to 
      host IgE.
PG  - 2873-80
AB  - In the development of a novel vaccine against atopic allergies, we have screened 
      for adjuvants that enhance the therapeutic antibody response against self 
      immunoglobulin E (IgE). The response against self IgE is induced by 
      administration of a vaccine antigen, which contains both self and non-self IgE 
      regions, together with an adjuvant. We evaluated five commonly used adjuvants; 
      Freund's, aluminium hydroxide, ISCOMs, Montanide ISA 51 and Montanide ISA 720, 
      and found that the mineral oil-based adjuvants; Montanide ISA 51 and Freund's 
      induced at least 5-10-fold higher anti-self IgE titers than any of the other 
      candidates. However, with one exception, Alum, the immune responses against the 
      carrier, i.e. the non-self regions, were similar for all adjuvants, indicating 
      that the ability to induce responses against self and non-self antigens differ 
      among adjuvants. The responses against non-self IgE were more than 50-fold higher 
      than antibody responses against self IgE in both the Freund's and Montanide 
      51-administered animals, indicating that the response against self molecules is 
      markedly inhibited by tolerance-inducing mechanisms. Co-administration of 
      Montanide ISA 51 with immuno-stimulatory substances from bacteria; 
      muramyldipeptide (MDP), monophosphoryl-lipid A (MPL) or a 
      formyl-methionine-containing tripeptide (fMLP), did not elevate the anti-self IgE 
      response. Hence, adjuvants based on pure mineral oil without additional 
      immuno-stimulatory substances appear to be the best adjuvant candidates in 
      therapeutic vaccines aimed at regulating the in vivo levels of self-proteins.
FAU - Johansson, Jeannette
AU  - Johansson J
AD  - Department of Cell and Molecular Biology, Biomedical Center, Box 596, Uppsala 
      University, S-751 24, Sweden.
FAU - Ledin, Anna
AU  - Ledin A
FAU - Vernersson, Molly
AU  - Vernersson M
FAU - Lovgren-Bengtsson, Karin
AU  - Lovgren-Bengtsson K
FAU - Hellman, Lars
AU  - Hellman L
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Autoantibodies)
RN  - 0 (Autoantigens)
RN  - 0 (Lipid A)
RN  - 0 (Plant Oils)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 53678-77-6 (Acetylmuramyl-Alanyl-Isoglutamine)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - 8020-83-5 (Mineral Oil)
SB  - IM
MH  - Acetylmuramyl-Alanyl-Isoglutamine/pharmacology
MH  - Adjuvants, Immunologic/*pharmacology
MH  - Aluminum Hydroxide/pharmacology
MH  - Animals
MH  - Autoantibodies/analysis/biosynthesis
MH  - Autoantigens/immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Hypersensitivity, Immediate/immunology
MH  - Immunization Schedule
MH  - Immunization, Secondary
MH  - Immunoglobulin E/analysis/*biosynthesis/*immunology
MH  - Lipid A/pharmacology
MH  - Mineral Oil/pharmacology
MH  - Opossums/immunology
MH  - Plant Oils/pharmacology
MH  - Rats
MH  - Rats, Wistar
EDAT- 2004/07/13 05:00
MHDA- 2004/10/19 09:00
CRDT- 2004/07/13 05:00
PHST- 2003/07/15 00:00 [received]
PHST- 2003/12/24 00:00 [accepted]
PHST- 2004/07/13 05:00 [pubmed]
PHST- 2004/10/19 09:00 [medline]
PHST- 2004/07/13 05:00 [entrez]
AID - S0264410X04000131 [pii]
AID - 10.1016/j.vaccine.2003.12.029 [doi]
PST - ppublish
SO  - Vaccine. 2004 Jul 29;22(21-22):2873-80. doi: 10.1016/j.vaccine.2003.12.029.